SC Asks Uttarakhand Govt To Finalize Decision On Suspension Of 14 Patanjali Products In Two Weeks

New Delhi: The Supreme Court on Tuesday directed the Uttarakhand government to decide on the suspension of 14 products by yoga guru Ramdev’s Patanjali Ayurved, reported Live Law.

A bench of Justices Hima Kohli and Sandeep Mehta directed the Bharatiya Janata Party government in the state to decide on the matter within two weeks.

On April 29, the Uttarakhand State Licensing Authority for Ayurvedic and Unani Services told the court that the licences were suspended as Patanjali Ayurved had repeatedly violated the 1945 Drugs and Cosmetic Rules.

The 14 drugs that had been suspended were: Swasari Gold, Swasari Vati, Bronchom, Swasari Pravahi, Swasari Avaleh, Mukta Vati Extra Power, Lipidom, Bp Grit, Madhugrit, Madhunashini Vati Extra Power, Livamrit Advance, Livogrit, Eyegrit Gold and Patanjali Drishti Eye Drop.

At the previous hearing on July 9, Patanjali Ayurved told a bench of Justices Hima Kohli and Sandeep Mehta that it had instructed 5,606 franchise stores to withdraw these products.

Media platforms were also instructed to withdraw advertisements for the 14 products, said the company. The court had asked Patanjali Ayurved to file an affidavit within two weeks, stating if social media intermediaries had withdrawn advertisements for the products.

At Tuesday’s hearing, the Indian Medical Association told the court that the 14 products were still available over the counter, even though Patanjali had earlier reportedly stopped their manufacturing.

Patanjali then told the court that the state government cancelled the suspension order on July 1 after considering the report of a committee constituted to look into the matter, reported Live Law.

Related Posts

  • Pharma
  • May 17, 2025
  • 17 views
Fire disrupts production at GSK Pharma’s contract manufacturing site

GlaxoSmithKline Pharmaceuticals (GSK Pharma) on Friday informed the stock exchanges that a fire had occurred at one of its contract manufacturing facilities, causing a temporary disruption in production at the…

  • Pharma
  • May 16, 2025
  • 103 views
Trump targets Big Pharma with drug price order; Indian generics seen gaining edge

US President Donald Trump’s move to slash prescription drug prices by tying them to rates in countries such as the UK and Germany may rattle multinational pharmaceutical giants, but it…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Fire disrupts production at GSK Pharma’s contract manufacturing site

Fire disrupts production at GSK Pharma’s contract manufacturing site

Trump targets Big Pharma with drug price order; Indian generics seen gaining edge

Trump targets Big Pharma with drug price order; Indian generics seen gaining edge

Emcutix and Mantra Pharma Introduce Ureaderm: Advanced Urea-Based Moisturizers for Indian Skin

Emcutix and Mantra Pharma Introduce Ureaderm: Advanced Urea-Based Moisturizers for Indian Skin

DCA seizes syrup stocks over misleading fever cure claim

DCA seizes syrup stocks over misleading fever cure claim

Mankind Pharma Faces Rs 341.86 Cr Tax Demand

Mankind Pharma Faces Rs 341.86 Cr Tax Demand

Piramal Pharma stock falls 5% after Q4 results; check key numbers here

Piramal Pharma stock falls 5% after Q4 results; check key numbers here